FHL2

Across TCGA pan-cancer cohorts, FHL2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated FHL2 data layer compared with 22 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher FHL2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FHL2 expression acts as an unfavorable survival marker.

OV, STAD, and BRCA are the cancer types where FHL2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.346	0.843	.003	18	view →
STAD	OS	Median	II,III,IV	0.183	0.660	.009	12	view →
BRCA	OS	Median	II,III,IV	0.167	0.565	.040	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

FHL2–OV (OS)

Open the OV breakdown →